Pediatric Cardiology

, Volume 33, Issue 7, pp 1013–1020

The Growing Epidemic of Hypertension Among Children and Adolescents: A Challenging Road Ahead

Review Article

Abstract

Currently, it is clear that primary hypertension begins in childhood and that it contributes to the early development of chronic kidney disease (CKD). Hypertension also increases the risk of cardiovascular morbidity and mortality, and that risk rises as blood pressure levels escalate. As among adult patients, overweight and obesity rates are on the rise among children and adolescents with primary hypertension and can develop target organ damage including left ventricular hypertrophy. An elevated level of C-reactive protein (CRP) and microalbuminuria are early manifestations of cardiovascular disease and CKD in hypertensive patients. Lifestyle interventions are recommended for all children with hypertension. Pharmacologic therapy should be added for symptomatic children, those with stage 2 hypertension, and children with prehypertension and stage 1 hypertension who exhibit an insufficient response to lifestyle modifications. Although the recommendations for choice of drugs generally are similar for children and adults, dosages for children should be lower, based on weight, and adjusted very carefully. Medications that are effective and safe for children and adolescents include thiazide diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, and calcium channel-blockers. Hypertension is not being detected early enough for initiation of a treatment regimen to reduce death and disability. Initiatives should be undertaken to make health care providers and the general population more aware of the seriousness of hypertension in children and adolescents. This review focuses on the principles underlying the importance of a team approach for hypertension control, especially one that incorporates increased data sharing using enhanced health information technology for early detection and intervention.

Keywords

Cardiovascular events Children and adolescents Chronic kidney disease Epidemic Hypertension Team approach 

References

  1. 1.
    Agrawal R, Bunaye Z, Beker DM (2008) Prognostic significance of between arm blood pressure differences. Hypertension 51:657–662CrossRefGoogle Scholar
  2. 2.
    Amin AP, Salisbury AC, McCullough PA, Gosch K, Spertus JA, Venkitachalam L et al (2012) Trends in the incidence of acute kidney injury in patients hospitalized with acute myocardial infarction. Arch Intern Med 172:246–253PubMedCrossRefGoogle Scholar
  3. 3.
    Assadi F (2002) Quantitation of microalbuminuria using random urine samples. Pediatr Nephrol 17:107–110PubMedCrossRefGoogle Scholar
  4. 4.
    Assadi F (2007) Effect of microalbuminuria lowering on regression of left ventricular hypertrophy in children and adolescents with essential hypertension. Pediatr Cardiol 28:27–33PubMedCrossRefGoogle Scholar
  5. 5.
    Assadi F (2008) Relation of left ventricular hypertrophy to microalbuminuria and C-reactive protein in children and adolescents with essential hypertension. Pediatr Cardiol 29:580–584PubMedCrossRefGoogle Scholar
  6. 6.
    Bianchi S, Bigazzi R, Campese VM (1999) Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis 34:973–995PubMedCrossRefGoogle Scholar
  7. 7.
    Calhoun DA, Jones D, Textor S et al (2008) Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 51:1403–1419PubMedCrossRefGoogle Scholar
  8. 8.
    Chobanian AV, Bakris GL, Black HR, Cushman WC (2003) The 7th report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 Report. JAMA 289:2560Google Scholar
  9. 9.
    Cutler DM, Everett W (2010) Thinking outside the pillbox-medication adherence as a priority for health care reform. N Engl J Med 362:1553–1555PubMedCrossRefGoogle Scholar
  10. 10.
    Daniels SR, Loggia JM, Hoary P, Kimball TR (1998) Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension. Circulation 97:1907–1911PubMedCrossRefGoogle Scholar
  11. 11.
    Falkner B, Kushner H, Onesti G, Angelakos ET (1981) Cardiovascular characteristics in adolescents who develop essential hypertension. Acta Paediatr 3:521–527Google Scholar
  12. 12.
    Flynn JT, Newburger JW, Daniels SR (2004) A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr 145:353–539PubMedCrossRefGoogle Scholar
  13. 13.
    Fonarow G, O’Neill W (2012) Blood pressure differences between arms could signal heart risk. 30 January 2012; Lancet online edition 4:24Google Scholar
  14. 14.
    Gaddam KK, Nishizaka MK, Pratt-Ubunama MN et al (2008) Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 168:1159–1164PubMedCrossRefGoogle Scholar
  15. 15.
    Graves JW, Althaf MM (2006) Utility of ambulatory blood pressure monitoring in children and adolescents. Pediatr Nephrol 21:1640–1652PubMedCrossRefGoogle Scholar
  16. 16.
    Greenlund KJ, Croft JB, Mensah GA (2004) Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999–2000. Arch Intern Med 164:2113–2118PubMedCrossRefGoogle Scholar
  17. 17.
    Hansen ML, Gunn PW, Kaelber DC (2007) Underdiagnosis of hypertension in children and adolescents. JAMA 298:874–879PubMedCrossRefGoogle Scholar
  18. 18.
    Hilgers KF, Dotsch J, Rascher W, Mann JF (2004) Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both? Pediatr Nephrol 19:956–961PubMedCrossRefGoogle Scholar
  19. 19.
    James P, Oparil S, Carter BL, et al (2012) The Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JNC 8 (in press). Retrieved at http://www.nhlbi.nih.gov/guidelines/hypertension/jnc8/index.htm
  20. 20.
    Lauer RM, Clarke WR (1989) Childhood risk factors for high adult blood pressure: the Muscatine study. Pediatrics 84:633–641PubMedGoogle Scholar
  21. 21.
    Litwin M, Niemirska A, Ruzicka M, Febber J (2009) White-coat hypertension in children: not rare and not benign? J Am Soc Hypertens 3:416–423PubMedCrossRefGoogle Scholar
  22. 22.
    McCambridge TM, Benjamin HJ, Brenner JS et al (2010) Athletic participation by children and adolescents who have systemic hypertension. Council on sports and fitness. Pediatrics 125:1287–1294PubMedCrossRefGoogle Scholar
  23. 23.
    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576CrossRefGoogle Scholar
  24. 24.
    Ogden CL, Carroll MD, Kit BK, Flegal KM (2012) Prevalence of obesity and trends in body mass index among U.S. children and adolescents, 1999–2010. JAMA 307:483–490PubMedCrossRefGoogle Scholar
  25. 25.
    Ohkubo T, Kikuya M, Asayama K, Obara T, Hara A et al (2006) Prognostic significance of nighttime, early morning, and daytime blood pressures on the risk of cerebrovascular and cardiovascular mortality: the Ohasama Study. J Hypertens 24:1841–1844PubMedCrossRefGoogle Scholar
  26. 26.
    Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353:487PubMedCrossRefGoogle Scholar
  27. 27.
    Pimenta E, Calhoun DA (2007) Resistant hypertension and aldosteronism. Curr Hypertens Rep 29:353–359CrossRefGoogle Scholar
  28. 28.
    Sakarcan A, Tenney F, Wilson JT et al (2001) The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol 41:742–749PubMedCrossRefGoogle Scholar
  29. 29.
    Sica DOA, White W (1999) Chronotherapeutics and its role in the treatment of hypertension and cardiovascular disease. Am J Hypertens 12:159–165PubMedGoogle Scholar
  30. 30.
    Sorof J, Daniels SR (2002) Obesity hypertension in children: a problem of epidemic proportions. Hypertension 40:44–447CrossRefGoogle Scholar
  31. 31.
    Sorof JM, Cargo P, Graepel J (2002) Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. Pediatr Nephrol 17:345–350PubMedCrossRefGoogle Scholar
  32. 32.
    Soffer B, Zhang Z, Miller K (2003) A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of linsinopril for children with hypertension. Am J Hypertens 16:795–800PubMedCrossRefGoogle Scholar
  33. 33.
    Tirosh A, Afek A, Rudich A et al (2010) Progression of normotensive adolescents to hypertensive adults: a study of 26,980 teenagers. Hypertension 56:203–209PubMedCrossRefGoogle Scholar
  34. 34.
    Walsh JM, McDonald KM, Shojania KG, Sundaram V, Nayak S, Lewis R et al (2006) Quality improvement strategies for hypertension management: a systematic review. Med Care 44:646PubMedCrossRefGoogle Scholar
  35. 35.
    Wells T, Frame V, Soffer B et al (2002) A double-blind, placebo-controlled, dose-response study of the effectiveness of enalepril for children with hypertension. J Clin Pharmacol 42(8):870–880PubMedCrossRefGoogle Scholar
  36. 36.
    The ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288:2981–2997Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Pediatrics, Section of NephrologyRush University Medical CenterChicagoUSA
  2. 2.HaverfordUSA

Personalised recommendations